The awarded license is valid for the manufacturing and distribution of DehydraTECH processed cannabinoid active pharmaceutical ingredient
Lexaria Bioscience, a global innovator in drug delivery platforms has announced the awarding of a five-year, non-exclusive DehydraTECH license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp. to AnodGen Bioceuticals of Ireland.
The awarded license is valid for the manufacturing and distribution of DehydraTECH processed cannabinoid active pharmaceutical ingredient (API) powders within Europe including the UK, Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids.
Anodgen will pay royalty fees to Lexaria for all API powders sold that utilise the DehydraTECH technology.
The partnership with Lexaria will help bring research-based API's and technology to companies and people with superior bioavailability and enhanced absorption
Anodgen has the right to manufacture and sell these API powders to third-party companies for their own products that are designated by a national regulator as a medical product, drug, nutraceutical, pharmaceutical or biopharmaceutical, as applicable, under its cannabinoid product license rights.
"This strategic alliance with Lexaria Bioscience Corp. underscores the focus of Anodgen to 'Bring Science to Life', in addition to our research and API's," said Dr Slimane Aboulkacem, Chairman and Founding Member of Anodgen Bioceuticals.
Dr Jeffrey Pruski, Anodgen's Chief Medical Officer and Founding Member mentioned that "the partnership with Lexaria will help bring research-based API's and technology to companies and people with superior bioavailability and enhanced absorption. This alliance will bring about change we will yet see in pharmacokinetics and formulation."
Consumer products purchased without physician or medical professional consultation are not permitted under the terms of this License. AnodGen is expected to have their new facility in Ireland fully operational later in 2022 and Lexaria recognises the long-term potential for growth in the utilisation of DehydraTECH across these pharmaceutical market opportunities.